Toxicology – Miscellaneous Antimicrobials

Core Concept

This older grouping combines several unrelated antimicrobial classes, so there is no single toxidrome. The clinically useful approach is to consider each drug separately.

Major agents include:

• Clindamycin and lincomycin
• Chloramphenicol
• Fluoroquinolones — ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin and others
• Vancomycin

Most isolated oral overdoses cause relatively mild GI symptoms. Important toxicity more often occurs from therapeutic exposure, drug interactions, excessive parenteral administration, or impaired clearance.

Characteristic problems are:

• Clindamycin → diarrhea and C. difficile infection
• Chloramphenicol → bone-marrow toxicity; neonatal gray syndrome
• Fluoroquinolones → CNS effects, dysglycemia, QT effects, tendinopathy and peripheral neuropathy
• Vancomycin → nephrotoxicity and infusion reaction

There is no universal antidote.

1. Clindamycin and Lincomycin

Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis through binding to the 50S ribosomal subunit.

Acute oral overdose is generally mild.

Possible effects include:

• Nausea
• Vomiting
• Abdominal discomfort
• Diarrhea

Severe toxicity is uncommon after an isolated ingestion.

Clindamycin and C. difficile

The most clinically important complication is disruption of normal intestinal flora followed by Clostridioides difficile infection (CDI).

This may develop:

• During therapy
• Shortly after therapy
• Even weeks after antibiotic exposure

Symptoms can include:

• Watery diarrhea
• Abdominal pain
• Fever
• Leukocytosis

Severe disease may progress to:

• Ileus
• Toxic megacolon
• Sepsis
• Shock

Modern CDI Diagnosis

Testing should be performed in an appropriate symptomatic patient rather than indiscriminately screening asymptomatic individuals.

Modern testing may involve:

• Stool toxin assays
• NAAT/PCR-based testing
• Multistep diagnostic algorithms

The historical use of routine stool occult blood testing, barium enema, or proctosigmoidoscopy is no longer the standard diagnostic approach.

Modern CDI Treatment

The old statement that antibiotic-associated colitis is simply treated with oral vancomycin needs refinement.

Modern treatment depends on:

• Severity
• Initial vs recurrent infection
• Patient risk factors
• Current infectious-disease guidelines

Fidaxomicin or oral vancomycin are commonly used depending on the clinical setting.

Antimotility drugs are generally avoided in severe or fulminant CDI, particularly when ileus or toxic megacolon is a concern.

Clindamycin – Other Toxicity

Less common effects include:

• Rash
• Hypersensitivity
• Hepatic injury
• Cytopenias
• Rare renal injury

Rapid IV administration has historically been associated with severe cardiovascular reactions, including:

• Hypotension
• Dysrhythmia
• Cardiovascular collapse

These are administration-related events rather than the usual presentation of oral overdose.

2. Chloramphenicol

Chloramphenicol inhibits bacterial protein synthesis at the 50S ribosomal subunit.

Systemic use is now limited in many settings because of serious hematologic toxicity.

The two major toxicologic concepts are:

1. Dose-related reversible bone-marrow suppression
2. Rare idiosyncratic aplastic anemia

These are distinct phenomena.

Dose-Related Bone-Marrow Suppression

High systemic exposure can suppress marrow function.

Possible findings include:

• Anemia
• Leukopenia
• Thrombocytopenia
• Pancytopenia

This form is generally related to dose/exposure and is usually reversible after discontinuation.

Idiosyncratic Aplastic Anemia

A separate and much more concerning reaction is rare aplastic anemia.

Important features:

• Not reliably dose dependent
• Can appear after therapy has stopped
• May be irreversible
• Can be fatal

This toxicity cannot be predicted simply from a chloramphenicol serum concentration.

Chloramphenicol – Gray Baby Syndrome

Neonates have limited capacity to metabolize and eliminate chloramphenicol.

Excessive systemic exposure can therefore produce gray baby syndrome.

Manifestations may include:

• Poor feeding
• Vomiting
• Abdominal distension
• Hypothermia
• Irregular respiration
• Cyanotic or gray discoloration
• Metabolic acidosis
• Hypotension
• Cardiovascular collapse

This is principally a neonatal pharmacokinetic toxicity rather than the typical manifestation of overdose in older children or adults.

Why Neonates Are Vulnerable

Neonates, especially premature infants, have immature:

• Hepatic glucuronidation
• Renal elimination

Therefore:

Reduced clearance → chloramphenicol accumulation → mitochondrial/cardiovascular toxicity

The historical term “gray baby syndrome” should not be generalized to toddlers.

Chloramphenicol Neurologic Toxicity

Prolonged exposure can rarely produce:

• Peripheral neuropathy
• Optic neuropathy
• Visual impairment

The old recommendation to treat chloramphenicol optic neuritis simply with large doses of B vitamins is not an established antidotal strategy.

The essential intervention is recognition and discontinuation of the offending drug, followed by ophthalmologic/neurologic assessment.

Chloramphenicol Concentrations

Serum concentrations can be useful during systemic therapy or suspected major parenteral dosing error.

However, a single historical threshold should not be treated as a universal predictor of toxicity.

Interpret concentrations according to:

• Age
• Dose
• Timing
• Hepatic function
• Renal function
• Clinical condition

3. Fluoroquinolones

Important modern fluoroquinolones include:

• Ciprofloxacin
• Levofloxacin
• Moxifloxacin
• Ofloxacin

Several agents listed in older references are now rarely used or unavailable in many countries.

Fluoroquinolones inhibit bacterial:

• DNA gyrase
• Topoisomerase IV

Acute overdose is usually mild, but this class has several important therapeutic adverse effects.

Fluoroquinolone GI Effects

Common effects include:

• Nausea
• Vomiting
• Abdominal discomfort
• Diarrhea

Antibiotic-associated diarrhea and CDI are also possible.

Fluoroquinolone CNS Toxicity

Neurologic and psychiatric effects can include:

• Headache
• Dizziness
• Insomnia
• Agitation
• Confusion
• Hallucinations
• Tremor
• Rare seizures

Risk may be increased by:

• Older age
• Renal impairment
• CNS disease
• High exposure
• Other medications that lower seizure threshold

Fluoroquinolone Seizures

If a toxicologic seizure occurs:

Benzodiazepines are first-line.

Persistent seizures are managed using standard toxicologic status-epilepticus principles.

Phenytoin is generally not preferred as the routine next treatment for medication-induced seizures.

Fluoroquinolone QT Prolongation

Some fluoroquinolones can delay cardiac repolarization.

The degree varies considerably by agent.

Moxifloxacin has particularly recognized QT-prolonging potential.

Risk increases with:

• Congenital long-QT syndrome
• Hypokalemia
• Hypomagnesemia
• Bradycardia
• Structural cardiac disease
• Other QT-prolonging medications

Torsades

For clinically important QT prolongation or torsades:

• Stop QT-prolonging medications
• Correct potassium
• Correct magnesium
• Give IV magnesium for torsades
• Use electrical treatment when unstable

Recurrent pause-dependent torsades may require selected heart-rate acceleration.

Fluoroquinolone Dysglycemia

Fluoroquinolones can disturb glucose regulation.

Both:

• Hypoglycemia
• Hyperglycemia

have been reported.

Risk is particularly relevant in patients with diabetes or those receiving glucose-lowering medication.

Therefore, altered mental status during fluoroquinolone treatment should include a bedside glucose check.

Tendinopathy and Tendon Rupture

A major modern safety issue is:

• Tendinitis
• Tendon degeneration
• Tendon rupture

The Achilles tendon is commonly involved, although other tendons can be affected.

Risk increases with factors such as:

• Older age
• Corticosteroid treatment
• Transplant status
• Renal dysfunction

This is primarily an adverse effect of therapeutic exposure rather than acute overdose.

Peripheral Neuropathy

Fluoroquinolones can rarely cause peripheral nerve injury.

Symptoms may include:

• Burning pain
• Tingling
• Numbness
• Altered sensation
• Weakness

Symptoms can occasionally persist after the drug has been stopped.

Other Important Fluoroquinolone Adverse Effects

Depending on the individual patient and agent, recognized concerns include:

• Photosensitivity
• Hepatic injury
• Renal injury/crystalluria with selected agents
• Severe hypersensitivity
• C. difficile infection
• Exacerbation of myasthenia gravis

Certain patients also require careful assessment of vascular/aortic risk during therapeutic prescribing.

These complications should not be interpreted as the expected findings after a single accidental ingestion.

Fluoroquinolones in Children

The historical blanket statement that fluoroquinolones must be avoided in everyone aged 17 years or younger is outdated.

They are not universally contraindicated in children.

Pediatric use may be appropriate for selected infections when:

• The organism or disease warrants therapy
• Suitable alternatives are unavailable
• Benefits outweigh musculoskeletal and other risks

Modern prescribing is indication-specific.

Fluoroquinolone Drug Interactions

Ciprofloxacin is an important inhibitor of CYP1A2.

It can increase concentrations of certain medications, particularly:

• Theophylline
• Caffeine
• Some other CYP1A2 substrates

Clinically important theophylline accumulation may cause:

• Vomiting
• Tachycardia
• Tremor
• Agitation
• Seizures
• Dysrhythmias

This should be recognized as an interaction-mediated toxicity.

Chelation in the GI Tract

Oral fluoroquinolone absorption can be substantially reduced by multivalent cations such as:

• Aluminum
• Magnesium
• Calcium
• Iron

This is an important therapeutic interaction but is not a treatment strategy for overdose.

4. Vancomycin

Vancomycin is a glycopeptide antibiotic used for serious gram-positive infections, including many infections caused by resistant organisms.

Its major toxicologic concerns are:

• Nephrotoxicity
• Infusion-related reaction
• Less commonly hematologic or auditory effects

Vancomycin Nephrotoxicity

Vancomycin-associated AKI is clinically important.

Risk increases with:

• High systemic exposure
• Prolonged therapy
• Critical illness
• Preexisting renal dysfunction
• Other nephrotoxic medications

Renal function should be monitored during significant systemic treatment.

Modern Vancomycin Monitoring

Older practice often focused heavily on trough concentrations.

For serious systemic infections, modern therapeutic monitoring increasingly uses AUC-guided exposure assessment rather than relying solely on a trough concentration.

The objective is to balance:

Adequate antimicrobial exposure ↔ reduced nephrotoxicity

This applies to therapeutic monitoring rather than routine evaluation of a small accidental ingestion.

Vancomycin Infusion Reaction

The historical term “red man syndrome” is increasingly replaced by:

Vancomycin infusion reaction

It is caused by non-IgE-mediated histamine release, usually associated with excessively rapid IV administration.

Manifestations include:

• Flushing
• Erythema
• Pruritus
• Warmth
• Upper-body rash
• Occasionally hypotension

Vancomycin Infusion Reaction vs Anaphylaxis

These are not the same process.

Vancomycin infusion reaction

Usually rate-related histamine release.

Anaphylaxis

IgE-mediated or otherwise mast-cell-mediated systemic hypersensitivity with potentially:

• Airway edema
• Bronchospasm
• Hypotension
• Generalized urticaria

True anaphylaxis requires standard emergency management with epinephrine as first-line therapy.

Management of Vancomycin Infusion Reaction

Management generally involves:

• Stop or slow the infusion
• Assess airway and hemodynamics
• Symptomatic antihistamine therapy when appropriate
• Resume more slowly if clinically necessary after symptoms resolve

Severe hypotension requires standard circulatory support.

Vancomycin Ototoxicity

Ototoxicity has historically been associated with vancomycin, but clinically important isolated vancomycin-induced hearing toxicity appears much less common than older literature suggested.

Risk may be greater with:

• Excessive exposure
• Other ototoxic drugs
• Preexisting hearing impairment

New tinnitus or hearing loss warrants evaluation.

Vancomycin Hematologic Effects

Prolonged exposure may rarely cause:

• Neutropenia
• Thrombocytopenia
• Immune-mediated cytopenias

These are generally therapeutic adverse reactions rather than acute overdose findings.

Oral Vancomycin

Oral vancomycin normally has minimal systemic absorption.

Therefore, its toxicity profile differs substantially from IV vancomycin.

Systemic absorption may increase in selected patients with:

• Severe intestinal inflammation
• Renal dysfunction
• Prolonged/high enteral exposure

This distinction is important when evaluating an exposure.

Diagnosis

Always identify:

• Exact antimicrobial
• Route
• Formulation
• Amount
• Timing
• Acute vs prolonged exposure
• Renal/hepatic function
• Coingestants
• Interacting medications

Because these drugs are unrelated pharmacologically, identifying the specific antibiotic is essential.

Laboratory Evaluation

Testing should be drug- and symptom-specific.

Chloramphenicol

Consider:

• CBC
• Electrolytes
• Renal function
• Acid–base assessment in severe toxicity
• Serum concentration when clinically appropriate

Clindamycin

With significant illness consider:

• CBC
• Electrolytes
• Renal/liver function
• Appropriate CDI testing for clinically significant diarrhea

Fluoroquinolones

Consider:

• Glucose
• Electrolytes
• Renal function
• ECG when QT risk exists
• Liver tests when indicated

Vancomycin

Consider:

• Creatinine
• Renal function trend
• Drug exposure monitoring during systemic therapy
• CBC when prolonged therapy or cytopenia is suspected

GI Decontamination

Do not induce vomiting.

Ipecac is obsolete.

Routine gastric lavage is also obsolete.

Activated charcoal may occasionally be considered following a substantial recent ingestion when:

• The agent is adsorbable
• The airway is safe
• Aspiration risk is acceptable
• The expected benefit justifies treatment

Most minor antibiotic ingestions do not require GI decontamination.

Hypotension

Significant hypotension should prompt assessment for:

• Volume depletion
• Infusion reaction
• Anaphylaxis
• Dysrhythmia
• Sepsis
• Coingestants

Appropriate isotonic crystalloid can be used when indicated.

Persistent vasodilatory shock generally favors norepinephrine rather than routine dopamine-first therapy.

Trendelenburg positioning is outdated.

Enhanced Elimination

There is no universal extracorporeal strategy for this group.

Dialysis usefulness depends on the individual antimicrobial’s:

• Protein binding
• Volume of distribution
• Molecular characteristics
• Renal clearance

It should therefore not be summarized simply as “dialysis works” or “dialysis does not work” for miscellaneous antibiotics.

Renal replacement therapy may also be required for conventional indications arising from severe AKI.

No Universal Antidote

There is no specific antidote for:

• Clindamycin
• Chloramphenicol
• Fluoroquinolones
• Vancomycin

Treatment is predominantly:

Stop exposure + supportive care + treat the specific complication

Observation

A fixed observation period is inappropriate for this diverse group.

Disposition depends on:

• Exact antibiotic
• Route
• Amount
• Symptoms
• ECG
• Renal/hepatic function
• Drug interactions
• Acute vs cumulative exposure
• Clinical trajectory

Some important adverse effects, such as aplastic anemia, tendinopathy, peripheral neuropathy, or CDI, cannot be excluded by a few hours of ED observation.

Admission

Hospitalization may be appropriate for:

• Persistent severe vomiting/dehydration
• Significant altered mental status
• Seizure
• Important QT prolongation or dysrhythmia
• Severe hypoglycemia
• Significant AKI
• Severe hepatic injury
• Gray baby syndrome
• Major infusion reaction
• Anaphylaxis
• Severe CDI
• Respiratory compromise

ICU care is appropriate for shock, status epilepticus, malignant dysrhythmia, respiratory failure, or severe neonatal chloramphenicol toxicity.

Pregnancy and Breastfeeding

The historical FDA pregnancy letter categories are obsolete.

Antimicrobial selection during pregnancy or breastfeeding should consider:

• Specific drug
• Infection severity
• Maternal condition
• Gestational/infant age
• Drug transfer
• Available alternatives
• Consequences of untreated infection

The historical blanket statement that fluoroquinolones must always be avoided during breastfeeding is too broad; decisions should be drug- and situation-specific using current lactation guidance.

Safeguarding

Rigid historical age thresholds for assuming neglect, abuse, or intentional poisoning are inappropriate.

Pediatric exposures should instead be evaluated according to:

• Developmental capability
• Medication accessibility
• Exposure circumstances
• Consistency of history
• Recurrent unexplained events
• Broader safeguarding concerns

Prognosis

Most isolated acute oral exposures have a favorable outcome.

However, important exceptions involve:

Chloramphenicol

• Severe neonatal accumulation
• Aplastic anemia

Clindamycin

• Severe C. difficile infection

Fluoroquinolones

• Severe CNS toxicity
• QT-related dysrhythmia
• Dysglycemia
• Persistent tendon or peripheral nerve complications

Vancomycin

• Significant AKI
• Severe infusion reaction or true anaphylaxis

Important Modernization of the Older Source

• “Miscellaneous antimicrobials” contains pharmacologically unrelated drugs and should be approached agent by agent.
• Clindamycin is strongly associated with C. difficile infection, which can occur during or after therapy.
• Modern CDI diagnosis relies on appropriate stool testing algorithms rather than routine occult blood testing, barium studies, or proctosigmoidoscopy.
• Modern CDI treatment commonly involves fidaxomicin or oral vancomycin, depending on the clinical scenario.
• Chloramphenicol causes both dose-related reversible marrow suppression and a separate rare idiosyncratic aplastic anemia.
• Gray baby syndrome is primarily a toxicity of neonates, especially premature infants, because of immature drug clearance.
• B vitamins are not an established antidote for chloramphenicol optic neuropathy.
• Fluoroquinolones can cause CNS effects, dysglycemia, QT prolongation, tendinopathy/tendon rupture, peripheral neuropathy, and exacerbation of myasthenia gravis.
• Fluoroquinolones are not absolutely prohibited in all children; selected pediatric indications exist.
• Ciprofloxacin can cause clinically important CYP1A2 interactions, particularly with theophylline.
• Vancomycin toxicity centers mainly on AKI and infusion-related reactions.
• “Red man syndrome” is better termed vancomycin infusion reaction.
• Vancomycin infusion reaction is not synonymous with anaphylaxis.
• Modern systemic vancomycin monitoring increasingly emphasizes AUC-guided exposure rather than trough concentration alone.
• Oral vancomycin usually has little systemic absorption.
• Ipecac and routine gastric lavage are obsolete.
• Trendelenburg and routine dopamine-first shock therapy are outdated.
• There is no universal observation period or extracorporeal treatment strategy for this diverse group.
• Historical FDA pregnancy categories are obsolete.

Key Points

• Clindamycin → GI effects and C. difficile infection.
• Chloramphenicol → reversible dose-related marrow suppression + rare idiosyncratic aplastic anemia + neonatal gray syndrome.
• Fluoroquinolones → CNS toxicity, dysglycemia, QT effects, tendinopathy, and peripheral neuropathy.
• Vancomycin → nephrotoxicity and rate-related infusion reaction.
• Severe acute overdose is uncommon with most of these antibiotics.
• Always distinguish acute overdose from adverse effects arising during prolonged therapeutic use.
• Drug interactions and renal dysfunction can substantially alter toxicity.
• There is no single antidote for this group.
• Management is primarily agent-specific supportive care and treatment of complications.